Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Omeros Corp (NQ: OMER ) 3.790 -0.230 (-5.72%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Omeros Corp < Previous 1 2 3 4 5 6 7 8 Next > ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm December 05, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Product Safety 12 Health Care Stocks Moving In Friday's After-Market Session December 03, 2021 Gainers Lixte Biotech Holdings (NASDAQ:LIXT Via Benzinga Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B December 02, 2021 Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200... Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 02, 2021 Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million... Via Benzinga Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion December 02, 2021 From Omeros Corporation Via Business Wire Omeros: Q3 Earnings Insights November 09, 2021 Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros... Via Benzinga Omeros Corporation Reports Third Quarter 2021 Financial Results November 09, 2021 From Omeros Corporation Via Business Wire 76 Biggest Movers From Yesterday November 11, 2021 Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... Via Benzinga Topics Initial Public Offering Exposures Securities Market Earnings Outlook For Omeros November 08, 2021 Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data November 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... Via Benzinga Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years November 05, 2021 Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA... Via Benzinga Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial November 05, 2021 From Omeros Corporation Via Business Wire Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis November 05, 2021 From Omeros Corporation Via Business Wire Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021 November 04, 2021 From Omeros Corporation Via Business Wire Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates November 02, 2021 The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... Via Benzinga 3 Beaten-Down Biotech Stocks -- Can They Recover? October 31, 2021 Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. Via The Motley Fool NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation October 22, 2021 San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements. Via SBWire 10 Biggest Price Target Changes For Tuesday October 19, 2021 Goldman Sachs boosted Walmart Inc. (NYSE:WMT) price... Via Benzinga 46 Biggest Movers From Yesterday October 19, 2021 Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... Via Benzinga Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA October 18, 2021 The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic... Via Benzinga Exposures Product Safety Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher October 18, 2021 Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities Benchmarks Pare Losses on Upbeat Earnings Outlook October 18, 2021 The major benchmarks are paring earlier losses at midday, fresh off of their best week in months as earnings season kicks off. Via Talk Markets 12 Health Care Stocks Moving In Monday's Intraday Session October 18, 2021 Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... Via Benzinga Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet October 18, 2021 Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the... Via Benzinga Topics Stocks Exposures US Equities Here's Why Omeros Is Sinking Further Today October 18, 2021 Bad news the company received today from the FDA surprised investors more than it probably should have. Via The Motley Fool Exposures Product Safety 34 Stocks Moving In Monday's Mid-Day Session October 18, 2021 Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... Via Benzinga Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates October 18, 2021 Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S.... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session October 18, 2021 Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.... Via Benzinga Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA October 18, 2021 From Omeros Corporation Via Business Wire The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology October 12, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... Via Benzinga Exposures COVID-19 < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.